Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab

por Roth, D A, Thompson, A, Tang, Y, Hammer, A E, Molta, C T, Gordon, D
Publicado 2015

Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA

por Collins, C E, Dall'Era, M, Kan, H, Macahilig, C, Molta, C, Koscielny, V, Chang, D J
Publicado 2016

Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care

por Bruce, I N, Urowitz, M, van Vollenhoven, R, Aranow, C, Fettiplace, J, Oldham, M, Wilson, B, Molta, C, Roth, D, Gordon, D
Publicado 2016